HOME >> BIOLOGY >> NEWS
Imprinting disorders and ART world's largest study results are reassuring

Further confirmation of a link between 'imprinting' disorders and assisted reproduction techniques (ART) was provided to the 21st annual conference of the European Society of Human Reproduction and Embryology today (Tuesday 21 June 2005). Dr. Alastair Sutcliffe, from the Department of Child Health, University College, London, UK, was reporting the results of the world's largest study into the relation between ART and four disorders known to be associated with aberrant genomic imprinting patterns.

Genetic imprinting is a mechanism in which gene expression depends upon parental origin. Mutations can alter normal imprinting, thus causing genetic abnormalities. Beckwith-Widermann syndrome (BWS) , Transient Neonatal Diabetes (TND), and Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are all acquired because of either a maternal or paternal deletion on a chromosome or from inheritance of both chromosomes of a pair from one parent.

"It has been known for some time that BWS, for example, was associated with ART", said Dr. Sutcliffe, "and we set out to look at the association of all four disorders and assisted conception." Dr. Sutcliffe and his team contacted patients throughout the UK who were in support groups for the disorders and obtained family histories and details of whether or not they had had ART, and if so, which kind. Out of 82 replies from families who had had a child with BWS, 10 had used ART in order to conceive (12%). Families with children with TND, AS, and PWS were also contacted and asked the same questions.

"We found that BWS was the only disorder where there was a significant risk for children conceived by ART", said Dr. Sutcliffe. "However, we found that all affected children apart from those with BWS had a mixture of genomic mutations, whereas those with BWS had a suggested mechanism maternal loss of methylation". Methylation is a mechanism used to inactivate parts of a chromosome to prevent problems.
'"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
20-Jun-2005


Page: 1 2

Related biology news :

1. New strategy for treating allergic disorders
2. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea
3. Double identities lie behind chromosome disorders
4. Study finds regions of DNA that appear linked to autistic spectrum disorders
5. Scientists find new agent to fight genetic disorders -- Zorro-Locked Nucleic Acid
6. Generalist genes linked to a variety of learning disorders
7. Eye movement tasks can be used to assess fetal alcohol spectrum disorders
8. Scientists uncover potential key to brain blood-flow disorders
9. Genetic mechanism helps explain chronic pain disorders
10. NIH launches Health Info Rx Program on newborn screening and related genetic disorders
11. Blame myelin for many neuropsychiatric disorders

Post Your Comments:
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: